Powder: -20°C for 3 years
In solvent: -80°C for 2 years
BMS-214662 is a potent and selective farnesyl transferase inhibitor that induces mitochondrial apoptosis in primitive CD34+ chronic myeloid leukemia (CML) stem cells/progenitors, and has the ability to selectively target CML stem cells/progenitors with antitumor activity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Synthesizing,6-8 weeks | $ 1,070.00 | |
50 mg | Synthesizing,6-8 weeks | $ 2,180.00 | |
100 mg | Synthesizing,6-8 weeks | $ 2,800.00 |
Description | BMS-214662 is a potent and selective farnesyl transferase inhibitor that induces mitochondrial apoptosis in primitive CD34+ chronic myeloid leukemia (CML) stem cells/progenitors, and has the ability to selectively target CML stem cells/progenitors with antitumor activity. |
Targets&IC50 | K-Ras:2.3 μM , Ras-CVLL:1.3 μM , farnesyl transferase:1.35 nM |
Molecular Weight | 489.61 |
Formula | C25H23N5O2S2 |
CAS No. | 195987-41-8 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 100 mg/mL (204.24 mM)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BMS-214662 195987-41-8 MAPK Raf BMS214662 BMS 214662 Inhibitor inhibitor inhibit